Nova Eye Medical Announces First Patient Enrolled in “MAGIC” Multi-Center Canaloplasty Trial for Glaucoma

Fremont, California, 30 April 2021 – Nova Eye Medical Limited, a medical technology company committed to advanced ophthalmic treatment technologies and devices, today announces the enrollment of the first glaucoma patient in the **M**ulti-center **A**b-interno **G**laucoma study **I**nvestigating **C**analoplasty (“MAGIC”) Trial.

According to the World Health Organisation, glaucoma is the world’s second leading cause of blindness, with the number of suspected cases of glaucoma estimated at over 60 million worldwide.

The first MAGIC patient was enrolled at the Eye Physicians & Surgeons of Arizona, Arizona, USA, by principal investigator Shamil Patel, MD.

According to Dr. Patel, the unique mechanism of ab-interno canaloplasty, which reduces outflow resistance in all parts of the natural drainage system, has a critical role in the glaucoma treatment armamentarium. Further, the ability to deploy ab-interno canaloplasty as a standalone procedure, and in combination with cataract surgery, supports its versatility in the glaucoma treatment algorithm.

“Ab-interno canaloplasty is akin to cardiac angioplasty for the eye. It employs a multimodal mechanism to address multiple points of blockage in the natural drainage system. Since first adopting the procedure in 2013 it has proven to be a highly effective treatment for the majority of my mild-to-moderate open-angle glaucoma patients. Most patients achieve post-operative pressures in the low teens following ab-interno canaloplasty,” said Dr. Patel.

The MAGIC Trial will be performed over a 12-month period and will enrol up to 160 patients with mild to moderate, uncontrolled primary open-angle glaucoma (POAG) on 1-4 medications. Patients will be randomized to treatment with either the iTrack™ canaloplasty microcatheter or the OMNI® surgical system (Sight Sciences). Ab-interno canaloplasty will be performed as a standalone procedure during the trial to eliminate the confounding effect of cataract surgery. Primary endpoints will

include reduction in mean intraocular pressure (IOP) and mean number of anti-glaucoma medications. Secondary endpoints will include surgical and post-operative complications.

Introduced in 2008, the Company's proprietary iTrack™ canaloplasty microcatheter is the world's first canaloplasty device. Further, it is the only device that enables the surgeon to customize the volume of ophthalmic viscosurgical device (OVD) – a hyaluronic acid-based gel-like substance – delivered during the ab-interno canaloplasty procedure in order to best meet the needs of each individual patient. In the MAGIC Trial, the impact of OVD volume in relation to clinical efficacy will be assessed.

According to lab testing conducted by the Company, the iTrack™ canaloplasty microcatheter delivers more OVD into Schlemm's canal than any other canaloplasty device. It also delivers OVD via a pressurized mechanism, designed to pop open herniations of the collector channels.

"With iTrack™ I take advantage of the capability to titrate the amount of OVD delivered based on the patency of Schlemm's canal. For example, I will deliver more OVD in cases where the canal is very occluded, in order to effectively break adhesions and push out herniations of the trabecular meshwork," said Dr. Patel.

A tissue-sparing, implant-free procedure with the added benefit of a simplified post-operative regimen, iTrack™ is routinely deployed by surgeons as an earlier stage intervention in the treatment of mild-moderate glaucoma patients.

"The pathogenesis of glaucoma is different in every patient. The challenge for surgeons is to assess which MIGS are best suited to their various patient populations. We are seeing an increasing number of surgeons turn to iTrack™ to clear obstructions throughout the natural drainage system and to re-open collector channels, before resorting to tearing tissue or moving beyond the natural drainage system to the subconjunctival space," commented Mr. Bankovich, President of Nova Eye Medical.

"Tissue-sparing, ab-interno canaloplasty is well suited to earlier in the disease process, prior to MIGS procedures which remove or tear tissue. Glaucoma is a multifactorial disease and will invariably progress in most patients. Further, due to

increasing life expectancy patients have a higher lifetime risk for glaucoma development and generally live longer when they do have glaucoma. By preserving tissue early in the disease process, iTrack™ reserves the option for future glaucoma treatments."

The MAGIC Trial is expected to reinforce the clinical utility of ab-interno canaloplasty in the treatment of mild-moderate glaucoma patients. The Company anticipates publication of the completed 12-month results in the second half of 2022.

Further information on the MAGIC Trial can be found via the links below:

- https://glaucoma-itrack.com/magic
- https://clinicaltrials.gov (NCT04769453)

OMNI® is a registered trademark of Sight Sciences, Inc.

ABOUT AB-INTERNO CANALOPLASTY

Canaloplasty was first introduced in 2005 as an alternative to trabeculectomy in the treatment of severe glaucoma, performed via an ab-externo approach. Over time, refinement of the procedure by physicians has seen canaloplasty performed via an ab-interno approach to preserve the conjunctiva and sclera. Today, canaloplasty is commonly deployed in clinical practice via an ab-interno approach in the treatment of mild and moderate glaucoma. Unlike other minimally invasive glaucoma surgery (MIGS) procedures, which bypass the natural drainage system or remove tissue, ab-interno canaloplasty is a tissue-sparing, implant-free procedure that acts to re-establish the function of the eye's natural drainage system – achieving an average reduction in IOP of 30% while also preserving the viability of future treatment options. As a result, an increasing number of surgeons are turning to ab-interno canaloplasty to manage their mild-moderate glaucoma patients.

For additional information about iTrack™ and ab-interno canaloplasty, please visit: www.glaucoma-iTrack.com

---

ABOUT NOVA EYE MEDICAL

Nova Eye Medical Limited is a medical technology company that develops, manufactures and sells a portfolio of proprietary ophthalmic treatment technologies and devices. Used by eye surgeons in more than 100 countries globally, these technologies include iTrack™ minimally invasive glaucoma surgery (MIGS), a consumable surgical device that restores the eye's natural outflow pathway to lower pressure inside the eye and to eliminate patient reliance on anti-glaucoma medications for mild-moderate glaucoma. The Molteno3® glaucoma drainage device platform is designed to enhance surgical utility and optimize clinical outcomes for long-term IOP control in cases of severe or complex glaucoma. It also offers the benefit of a simplified and faster surgical profile. With its sales headquarters based in Fremont, California, Nova Eye Medical is supported by sales offices in Adelaide, Australia and Berlin, Germany, and a global network of more than 50 distribution partners. Manufacturing facilities are located in Fremont, California and Dunedin, New Zealand.

For additional information about Nova Eye Medical and its technologies, please visit: www.nova-eye.com

Media enquires:
Kate Hunt
Nova Eye Medical Limited
W +61 404 080 679
khunt@nova-eye.com

Investor enquires:
Dr. Tom Duthy
Nova Eye Medical Limited
W +61 402 493 727
tduthy@nova-eye.com